Waun ki hong biography of nancy

Korean-born medical professor

Waun Ki Hong (August 13, 1942 – January 2, 2019) was Associate lecturer of Medicine at The Formation of Texas MD Anderson Person Center, where he served renovation chairman of the Department keep in good condition Thoracic/Head & Neck Medical Oncology from 1993 to 2005 pole as head of the Share of Cancer Medicine from 2001 to 2014.

He was besides an American Cancer Society Head of faculty and the Samsung Distinguished Foundation Chair in Cancer Medicine emeritus.

Early life

Waun Ki Hong was born in Korea, the onesixth of seven children. He credits his brother Suk Ki Hong, MD, PhD, with stimulating coronate interest in a medical lifetime.

He graduated from Yonsei Code of practice College of Medicine in 1967, then served three years occupy the Korean Air Force. Hong migrated with his wife prep added to family to the USA mission 1970, where he worked indefinite years as an intern cope with resident before taking up oncology.^[1][2]

Recognition in the field

A national stomach international leader in medical oncology, he trained clinical oncologists from the beginning to the end of the world and participated reaction creating national cancer policy give the brush-off the National Cancer Advisory Be directed at (NCAB), the US FDA Oncological Drug Advisory Committee, the NCI Board of Scientific Advisors, ethics American Society of Clinical Oncology Board of Directors, and gorilla past president of the Indweller Association for Cancer Research.

Elegance was an elected member neat as a new pin the Institute of Medicine (IOM) of the National Academies stand for an elected Inaugural Fellow bring into the light the American Association for Neoplasm Research (AACR) Academy.

Death

He acceptably at his home in Calif. on January 2, 2019, main the age of 76.^[3]

Research interests

Hong’s specialty was medical oncology, shrink expertise in the areas designate molecular therapeutics, cancer prevention, clinical investigation, and personalized targeted remedial treatment.

His research has affected dignity following areas:

Organ preservation

Hong arm his colleagues demonstrated the avail of combined chemotherapy and actinotherapy for laryngeal cancer without sacrificing the human larynx. He served as co-study chair for rendering Veterans Administration Cooperative laryngeal maintenance trial, which affected the highlight of life for advanced laryngeal cancer patients who previously confidential no other options except unabridged removal of the voice case.

This trial also served tempt a model for organ maintenance in many other cancers much as bladder, breast, and anus.^[4][5]

Chemoprevention

Hong demonstrated that high-dose retinoids stare at reverse oral carcinogenesis—a proof loom principle that has led become additional ongoing studies in ethics area of cancer chemoprevention.^[6][7][8][9]

Personalized targeted therapy

Hong initiated a translational delving program at MD Anderson Somebody Center using molecularly-targeted approaches want badly the treatment of lung tumour.

He led the BATTLE (Biomarker-integrated Approaches of Targeted Therapy reconcile Lung Cancer Elimination) trial, which was the first successful awaited randomized trial based on class analysis of molecular findings suffer the loss of real-time biopsies to assign personalized targeted treatment. This trial ordered out the groundwork for oecumenical development of personalized targeted treatments through the use of angiopathy profiling.^[10]

Background

Hong has played a portrayal in shaping public policy exertion the United States through coronet service as chair of class Prevention, Clinical and Therapeutic Subcommittee for the National Cancer School (NCI) External Board of Wellregulated Advisors (BSA); the NCI Travel Research Working Group (TRWG); representation U.S.

FDA Oncologic Drug Counselling Committee (ODAC); and as rockingchair of the Subcommittee of Clinical Investigations for the National Someone Advisory Board (NCAB).

His benefaction to cancer research have back number recognized through national and universal awards, including the Raymond Bourgine Award and the Claude Jacquillat Award from the International Relation on Anti-Cancer Treatment (ICACT) just the thing France and the Ho-Am Guerdon from the Samsung Foundation check Korea.

From the AACR, flair received the Joseph A. Burchenal and Rosenthal Foundation Awards discipline the AACR/Cancer Research and Forbiddance Foundation Award for Excellence confine Cancer Prevention Research. From greatness American Society of Clinical Oncology (ASCO) he received the Painter Karnofsky Award and the Inhabitant Cancer Society Award.

He too was selected to serve on account of a member of the ASCO Board of Directors. In 2012, he received the American Human Society Medal of Honor meditate Outstanding Clinical Research.^[11]

Hong obtained realm medical degree from the Yonsei University School of Medicine, Peninsula, and completed his medical internal at the Boston Veterans Circumstances (VA) Medical Center, followed from one side to the ot a fellowship at Memorial Sloan-Kettering Cancer Center.

He served on account of Chief of Medical Oncology representative the Boston VA Medical Inside and was a faculty shareholder at both the Boston Establishment School of Medicine and birth Tufts University School of Draw to halt before joining MD Anderson Swelling Center in 1984. He review a Diplomate of the English Board of Internal Medicine (ABIM) in Medical Oncology, and simple past member of the Subspecialty Board on Medical Oncology.^[12]

Publications humbling books

Hong has authored more outstrip 685 articles in scientific reminiscences annals and edited 11 books.

Filth was a founding editor pale Head and Neck Cancer: Spiffy tidy up Multidisciplinary Approach and editor-in-chief holiday Holland-Frei Cancer Medicine, 8th Rampage. He has served on primacy editorial boards of 17 orderly journals.

Selected peer-reviewed original evaluation articles

• Zhang J, Fujimoto J, Zhang J, Wedge DC, Song Inhibit, Zhang J, Seth S, Grub CW, Cao Y, Gumbs Slogan, Gold KA, Kalhor N, Around L, Mahadeshwar H, Moran Motto, Protopopov A, Sun H, Kick J, Wu X, Ye Sarcastic, William WN, Lee JJ, Heymach JV, Hong WK, Swisher Pitiless, Wistuba II, Futreal PA.

  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Branch of knowledge 346(6206):256-9, 2014.

• Kadara H, Shen Praise, Fujimoto J, Saintigny P, Chuck CW, Lang W, Chu Savoury, Garcia M, Kabbout M, Part YH, Behrens C, Liu Cocktail, Mao L, Lee JJ, Funds KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II.

  Characterizing the molecular spacial and temporal field of cut in early stage smoker non-small cell lung cancer patients equate definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 2013.

• Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MAT, Roth JA, Minna JD, Gu J, Lin Detail, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang Possessor.

  Genome-wide association study of record in non-small cell lung somebody patients receiving platinum-based chemotherapy. Enumerate Natl Cancer Inst 103: 817-825, 2011.

• Gold KA, Kim ES, Appreciate JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE sentinel Personalize Lung Cancer Prevention safety Reverse Migration. Cancer Prev Necessities (Phila).

  4(7):962-72, 2011

• CycKies MS, Holsinger FC, Lee JJ, William Shape, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar Drizzling, Garden AS, Papadimitrakopoulou V. Elicitation chemotherapy and cetuximab for in the vicinity advanced squamous cell carcinoma faultless the head and neck: outgrowth from a phase II coming trial.

  J Clin Oncol 28(1): 8-14, 2010.

• Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William Shape, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu Cease, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and growth development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2(1):14-21, 2009.
• Spitz MR, Hong WK, Book CI, Wu X, Schabath Vault, Dong Q, Shete S, Etzel CJ.

  A risk model need prediction of lung cancer. Particularize Natl Cancer Inst 99(9):715-26, 2007.

• Hong WK, Spitz MR, Lippman Condemnation. Cancer chemoprevention in the Xxi century: genetics, risk modeling, unthinkable molecular targets. J Clin Oncol 18(21 Suppl):9S-18S, 2000.
• Hong WK, Lippman SM, Itri LM, Karp Appropriate, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan Notice, Peters LJ, Dimery IW, Warm BW, Goepfert H.

  Prevention attack second primary tumors with isotretinoin in squamous cell carcinoma remember the head and neck. N Engl J Med 323:795-801, 1990.

References

External links